Fitness Trends Gynecological Cancer Drugs Market | Page 2

version of Doxil, which is a chemotherapy drug used in the treatment of certain cancer such as
ovarian cancer, AIDS-related Kaposi's sarcoma, and multiple myeloma.
Furthermore, in 2017, US FDA also approved Zejula (niraparib), which is targeted therapy drug
for women with some types of ovarian, fallopian tube, or peritoneal cancers. It is also approved
for women with relapsed cancer after chemotherapy. American Cancer Society, as of March
2018 has funded around 22 grants for cervical cancer, which accounted for around US$ 9.3
million. The funding value is offered to a single or group of research, which includes a specific
type of a cancer or area of cancer.
Increasing prevalence of gynecological cancers, is expected to be a major factor for growth of
the market. According to American Cancer Society, endometrium cancer, a type of cervical
cancer, was estimated to be the most common cancer of the female reproductive organs.
Furthermore, it was also estimated that 47,130 new cases of endometrial cancer will be
diagnosed in the U.S. in 2012, and about 8,010 women will die from endometrial cancer.
Moreover, according to American Cancer Society, ovarian cancer is the eighth most common
cancer among women and in 2012 it was estimated that about 22,280 new cases of ovarian
cancer will be diagnosed in the U.S., which is expected to support growth of the gynecological
cancer drugs market size over the forecast period.
Gynecological Cancer Drugs Market - Regional Insights
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin
America, Middle East, and Africa. North America accounted for the largest share in the
gynecological cancer drugs market, followed by Europe market in 2016. This is attributed to
increasing prevalence of cervical cancer in the U.S. According to Center for Disease Control and
Prevention in 2014, 12,578 women in the U.S. ware diagnosed with cervical cancer and 4,115
women died from cervical cancer. Therefore, this is expected to lead to increasing demand for
gynecological cancer drugs in North America.
Furthermore, Asia Pacific is estimated to grow at faster rate due to large population pool and
government initiatives to create awareness regarding gynecological cancer. For instance, the
Indian government published an operational framework for the country’s first national screening
programmne, in 2016, where there will be mandatory screening for oral, breast, and cervical
cancer in people over the age of 30 in 100 districts of India.